A cure too soon? Theoretical model explains COVID-19 rebound
Infectious virus particles still target cells despite early Paxlovid treatment
Approved by the Food and Drug Administration in 2023 for people at risk of severe disease, hospitalization and death, nirmatrelvir-ritonavir (Paxlovid) is a widely used COVID-19 antiviral pill. While nirmatrelvir-ritonavir works best when prescribed within the first five days of symptoms, a Los Alamos National Laboratory-led study found the standard five-day treatment may not be fully effective in eradicating the virus.
Target cells vulnerable to reinfection may remain in the body and allow the virus to rebound, especially with early treatment.
Why this matters: Patients believing they have received an effective treatment can still experience a viral rebound as well as spread the virus to others. The study suggested that a 10-day regimen of nirmatrelvir-ritonavir could be more effective in reducing a person's risk of a rebound and give the body enough time to develop a robust immune response.
What they did: After learning about some patients who experienced a rebound after early nirmatrelvir-ritonavir treatment, scientists in the Lab’s Theoretical Biology and Biophysics group used a mathematical model to analyze how viral loads change over the course of infection and treatment.
- Based on data from 51 patients who underwent nirmatrelvir-ritonavir therapy at Massachusetts General Hospital, the model explained why rebound was observed in 20 of them.
- The drug is cleared from the body before an adaptive immune response can develop and residual viable viruses can rebound if there are sufficient target cells remaining, especially if the treatment is administered too early.
- The model was deemed accurate for both patients who rebounded and those who did not.
Funding: National Institutes of Health, Laboratory Directed Research and Development at Los Alamos National Laboratory, Massachusetts Consortium on Pathogen Readiness, Massachusetts General Hospital Department of Medicine
LA-UR-25-26070
Share
Stay up to date
Subscribe to Stay Informed of Recent Science, Technology and Engineering Highlights from LANL
Subscribe NowMore STE Highlights Stories
STE Highlights Home
A surprising use for distorted data to glean hidden laws
Scientists explore the use of metastable data for machine learning to study complex systems
When magnetism becomes superconductivity's ally
In nickelate thin films, superconductivity vanishes — then reappears — as the magnetic field grows stronger
Making tiny glass parts? Try printing them
Los Alamos method builds small glass components layer by layer
Valley fever’s far-flung travels captured by machine learning
Los Alamos scientists study the genomes of fungi in complex environments to understand their impact
Society of Petroleum Engineers honors Los Alamos scientist for high-volume peer reviews
Meng is associate editor of 2 journals
Proton radiography team receives NNSA Defense Programs Award of Excellence
Plutonium experiments support the nation’s nuclear weapons program